AegirBio AB Logo

AegirBio AB

Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.

AEGIR | ST

Overview

Corporate Details

ISIN(s):
SE0014401121 (+3 more)
LEI:
549300MWGS283WZLYI10
Country:
Sweden
Address:
Scheelevägen 27, 223 63 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Magnasense AB, formerly AegirBio AB, is a diagnostics company specializing in developing innovative, saliva-based solutions for health monitoring. The company's core technology platform enables the creation of user-friendly, non-invasive tests for personalized diagnostics. Magnasense focuses on preventative care, such as oral health, and chronic disease management, particularly through Therapeutic Drug Monitoring (TDM) to optimize the dosage of biological drugs. Its products are designed for both professional healthcare settings and at-home use, aiming to make precision diagnostic testing more accessible, simple, and convenient for individuals and providers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all AegirBio AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AegirBio AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AegirBio AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-04-04 Bradley Messmer Other Other 499,829 N/A
2023-01-16 Fredrik Häglund Other Other 45,244 85,511.16 SEK
2022-12-09 Raphaela Heussen Other Other 37,689 N/A
2021-10-27 Martin Linde Other Other 370,000 N/A
2021-10-26 Anders Ingvarsson Other Other 120,000 N/A
2021-09-22 Patrik Elfwing Other Buy 2,000 519,200.00 SEK
2021-09-16 Anders Ingvarsson Other Other 120,000 N/A
2021-06-28 Gunnar Telhammar Other Sell 460 47,288.00 SEK
2021-06-17 Fredrik Häglund Other Other 245,397 1,840,477.50 SEK
2021-06-17 Martin Linde Other Other 160,263 1,169,919.90 SEK

Peer Companies

Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France
EAPI

Talk to a Data Expert

Have a question? We'll get back to you promptly.